MWG Stock Overview
A clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
InMed Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.39 |
| 52 Week High | US$15.80 |
| 52 Week Low | US$1.68 |
| Beta | 0.71 |
| 11 Month Change | -19.00% |
| 3 Month Change | -35.35% |
| 1 Year Change | -33.08% |
| 33 Year Change | -99.39% |
| 5 Year Change | -99.84% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| MWG | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 4.8% | -1.2% | -0.02% |
| 1Y | -33.1% | -20.1% | 8.2% |
Return vs Industry: MWG underperformed the German Pharmaceuticals industry which returned -22% over the past year.
Return vs Market: MWG underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| MWG volatility | |
|---|---|
| MWG Average Weekly Movement | 25.0% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MWG's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: MWG's weekly volatility has decreased from 49% to 25% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 13 | Eric Adams | www.inmedpharma.com |
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products.
InMed Pharmaceuticals Inc. Fundamentals Summary
| MWG fundamental statistics | |
|---|---|
| Market cap | €2.98m |
| Earnings (TTM) | -€6.55m |
| Revenue (TTM) | €4.76m |
0.6x
P/S Ratio-0.5x
P/E RatioIs MWG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MWG income statement (TTM) | |
|---|---|
| Revenue | US$4.96m |
| Cost of Revenue | US$3.39m |
| Gross Profit | US$1.57m |
| Other Expenses | US$8.39m |
| Earnings | -US$6.82m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.21 |
| Gross Margin | 31.71% |
| Net Profit Margin | -137.42% |
| Debt/Equity Ratio | 0% |
How did MWG perform over the long term?
See historical performance and comparison